NCT06166329 Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study
| NCT ID | NCT06166329 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Rouen |
| Condition | Non-severe Pulmonary Embolism |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-02-09 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2024-02-09 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to evaluate the prognostic performance of the chair lift test in the initial assessment of the severity of non-severe pulmonary embolism in hospitalized patients, in comparison with the current pulmonary embolism risk stratification score using the sPESI score refined by the use of cardiac biomarkers and right ventricular dysfunction
Eligibility Criteria
Inclusion Criteria: * Diagnosis of pulmonary embolism according to clinical algorithm, confirmed by thoracic angioscan or ventilation perfusion (V/P) scan, * Non-serious pulmonary embolism, not requiring intensive care (thrombectomy or fibrinolysis not considered). * sPESI score ≥ 1 \[or = 0 with elevated troponin or presence of markers of VD dysfunction, or = 0 with need for hospitalization due to comorbidities unrelated to PE (social isolation, comprehension disorders, intercurrent infection, chronic renal failure, advanced cancer...) * Patients with no contraindications to chair lift testing (no O2 at the time of testing). * Effective anticoagulation for at least 1 hour. Exclusion Criteria: * sPESI score = 0 with outpatient referral. * Diagnostic confirmation of Pulmonia Embolism by thoracic angioscan or scintigraphy more than 24h after suspicion of diagnosis. * Hospitalization \> 24h after introduction of anticoagulation, with subsequent confirmation by scintigraphy. * Any sign of serious Pulmonia Embolism, requiring hospitalization in an intensive care unit. * Asymptomatic Pulmonia Embolism discovered by chance
Contact & Investigator
Delphine SIMON, MD
PRINCIPAL INVESTIGATOR
University Hospital, Rouen
Frequently Asked Questions
Who can join the NCT06166329 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-severe Pulmonary Embolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06166329 currently recruiting?
Yes, NCT06166329 is actively recruiting participants. Contact the research team at delphine.simon@chu-rouen.fr for enrollment information.
Where is the NCT06166329 trial being conducted?
This trial is being conducted at Rouen, France.
Who is sponsoring the NCT06166329 clinical trial?
NCT06166329 is sponsored by University Hospital, Rouen. The principal investigator is Delphine SIMON, MD at University Hospital, Rouen. The trial plans to enroll 180 participants.